Advertisement

Supply Chain



While the Food and Drug Administration requires devicemakers to conduct postmarket surveillance to monitor the safety of their products, they often wait too long before recalling devices, according to a study published in Production and Operations Management.

While Marathon Pharmaceuticals' $89,000 price tag for its Duchenne muscular dystrophy drug Emflaza garnered much criticism last week, Marathon CEO Jeff Aronin insists the treatment will be affordable for patients, reports Chicago Tribune.

Here are four drugs and medical devices approved by the Food and Drug Administration this past week.

Advertisement

Most Read

Advertisement
Advertisement